Delivery Order SPE2DB22D2206-SPE2DB24FHJ12
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of the pharmaceutical product MOUNJARO 5 MG/0.5 ML PEN 0.5ML. The contract has a ceiling value of $1,578.00 and a completion date of May 23, 2024. It was awarded by the Defense Logistics Agency (DLA), a defense agency that provides logistics, acquisition, and technical services to the U.S. Armed Forces and other government agencies. Amerisourcebergen holds a significant Indefinite...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, is for the supply of the medication MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML to the Defense Logistics Agency (DLA). The $1,506.00 delivery order contract has an ultimate completion date of April 30, 2024. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of the pharmaceutical product MOUNJARO 12.5 MG/0.5 ML PEN 0.5ML. The contract, awarded by the Defense Logistics Agency (DLA), is a Delivery Order with a Firm Fixed Price of $1,052.00 and an ultimate completion date of May 21, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued up to $999,999,999.00 through December 31, 2025,...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML, a pharmaceutical product. The contract, with a ceiling value of $3,104.08, was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of June 13, 2024. This is a delivery order contract with a firm fixed price pricing type. The contract does not have a set-aside designation. Amerisourcebergen Drug Corp...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of the pharmaceutical product MOUNJARO 12.5 MG/0.5 ML PEN 0.5ML. The $2,035.40 firm-fixed-price delivery order was awarded on May 6, 2024 by the Defense Logistics Agency (DLA), with a completion date of May 7, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of the pharmaceutical product MOUNJARO 15 MG/0.5 ML PEN 0.5ML. The $3,156.00 firm fixed price delivery order was issued by the Defense Logistics Agency (DLA), which is a defense agency. The contract has a completion date of May 7, 2024. Amerisourcebergen, a major pharmaceutical distribution company, holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical as...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of the pharmaceutical product MOUNJARO 5 MG/0.5 ML PEN 0.5ML. The $5,260.00 fixed-price delivery order was awarded on June 5, 2024 by the Defense Logistics Agency (DLA), with a scheduled completion date of June 6, 2024. Amerisourcebergen holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of the pharmaceutical product MOUNJARO 5 MG/0.5 ML PEN 0.5ML. The $14,906.00 firm fixed price contract was awarded by the Defense Logistics Agency (DLA) Troop Support Medical on June 24, 2024, with a completion date of June 25, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is a delivery order for the pharmaceutical product MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML. The contract has a ceiling value of $1,315.00 and was awarded by the Defense Logistics Agency (DLA), a defense agency, on April 25, 2024 with a completion date of April 26, 2024. The contract is a firm fixed price arrangement without a set-aside designation. Amerisourcebergen, a major pharmaceutical distribution company, holds...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the pharmaceutical product MOUNJARO 15 MG/0.5 ML PEN 0.5ML. The $2,439.79 firm-fixed-price delivery order was issued by the Defense Logistics Agency (DLA), a defense agency, and has a completion date of May 3, 2024. Amerisourcebergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical to provide a wide range of pharmaceutical products and medical...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB24FHJ12Delivery Order
This federal contract award to Amerisourcebergen Drug Corp, Corporate Office Division, is for the delivery of the pharmaceutical product MOUNJARO 7.5 MG/0.5 ML PEN 0.5ML. The contract, valued at $22,381.64, was awarded by the Defense Logistics Agency (DLA), a defense agency, on May 22, 2024, with a completion date of May 23, 2024. The contract is a Delivery Order with a Firm Fixed Price pricing type and does not have a set-aside designation. Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. Additionally, the company holds a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs, valued up to $750,000 through May 2024.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $22.4k | 5/22/24 |